Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharmacia Biotech AB

Division of Pfizer Inc.

Latest From Pharmacia Biotech AB

Eyeballing HIV Drug Resistance Testing

Visible Genetics is on track to become the first company to offer a low-cost, rapid, easy-to-use system for clinical diagnostic genotyping using DNA sequencing, starting with HIV drug resistance testing. The company anticipates FDA approval by the end of the year for its HIV GeneKit. Not only does it want to secure a first-mover advantage in HIV resistance testing, but by giving away its DNA sequencer, VGI intends to use this footprint to introduce HCV, HBV and, potentially, cancer diagnostics. And while its sequencing system is not as high throughput as those used in central reference labs, VGI expects to penetrate the market by establishing the capability for decentralized clinical diagnostic technology.ts management team in the past year. Its statements on FDA approval have been as aggressive as its corporate moves.
Medical Device Strategy

Qiagen's Coup in DNA Sample Prep

Qiagen's success in exploiting an overlooked niche in research diagnostics--sample prep for nucleic acid tests--has driven an extraordinary growth story. But its performance has attracted the attention of big diagnostics companies. As it looks to expand into clinical markets, it faces levels of competition it's never seen before.
BioPharmaceutical Medical Device

Soane Biosciences Inc.

Miniaturization & microfluidics. Soane hopes to build the "laboratory-on-a-chip" to integrate lab procedures onto microchips. The company intends to build Nintendo-like plug-and-play systems, featuring a bench-top instrument and disposable plastic chipsencoded with the reagents and reaction spaces necessary to perform multi-step experiments.
BioPharmaceutical Medical Device

Perkin-Elmer Eyes the Value Chain

Perkin-Elmer built the machines that enabled the boom in genomics research--automated DNA sequencers. Genomics companies have done well, but Perkin-Elmer hasn't. The company is prepared to spend up to $1 billion over the next several years on external collaborations and acquisitions in an effort to climb the value chain and capture high-value applications of its tools for itself.
BioPharmaceutical Business Strategies
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register